Precision Oncology and Evolving Systemic Therapy in Differentiated Thyroid Cancer

Lori Wirth, MD, discusses the latest NCCN guideline updates in differentiated thyroid cancer.

Lori Wirth, MD, discusses the latest NCCN guideline updates in differentiated thyroid cancer.

Lori Wirth, MD, explains how molecular profiling in advanced differentiated thyroid cancer informs both treatment selection and prognosis. Identifying actionable genomic alterations enables clinicians to tailor systemic therapy based on tumor genotype, a cornerstone of precision oncology.

Lori Wirth, MD, reviews recent National Comprehensive Cancer Network guideline updates for patients with radioactive iodine refractory differentiated thyroid cancer.

Lori Wirth, MD, reviews emerging phase 3 data evaluating dabrafenib plus trametinib in patients with BRAF V600E–mutated advanced differentiated thyroid cancer.

Lori Wirth, MD, outlines optimal first-line use and sequencing strategies for systemic therapy in radioactive iodine–refractory differentiated thyroid cancer.

Lori Wirth, MD, discusses how the expanding treatment landscape in advanced differentiated thyroid cancer has shifted focus toward optimal sequencing of therapies.

Lori Wirth, MD, reviews clinical evidence supporting the combination of lenvatinib and pembrolizumab in radioactive iodine–refractory differentiated thyroid cancer.

Lori Wirth, MD, discusses practical considerations for managing adverse events with the combination of lenvatinib and pembrolizumab in radioactive iodine–refractory differentiated thyroid cancer.

Lori Wirth, MD, highlights future directions in the treatment of radioactive iodine–refractory differentiated thyroid cancer, emphasizing novel targets and mechanisms of resistance.